Cogent Biosciences Inc — Quarterly Financial Statistics (NASDAQ:COGT) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Cash from operating activities 51.98 M60.58 M66.51 M54.54 M64.29 M79.11 M 264.44 M Cash from investing activities -60.19 M14.88 M69.38 M8.91 M-1.53 M322.77 M 399.53 M Cash from financing activities 624 K26 K24.97 M47.23 M217.37 M588.67 M 878.23 M Free cash flow 51.7 M60.5 M65.96 M54.41 M64.22 M78.29 M 262.89 M

Notizie

Why Is Pfizer Stock Rising Tuesday? - Pfizer (NYSE:PFE)

Il titolo di Cogent Biosciences sale dopo la designazione di terapia innovativa della FDA

Cogent Biosciences stock rises after FDA grants breakthrough therapy status

Cogent's New Stomach Cancer Treatment Cuts Progression Risk In Half, Gets Breakthrough Therapy Tag - Cogent Biosciences (NASDAQ:COGT)

Thursday’s Insider Activity: GameStop CEO’s $21M Buy Stands Out

Fairmount Funds vende azioni Cogent Biosciences (COGT) per 127,4 milioni di dollari

Cogent mantiene il rating Buy di H.C. Wainwright grazie ai piani per nuove NDA

Cogent stock maintains Buy rating at H.C. Wainwright on NDA plans

Cogent Biosciences, Inc. (COGT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Raymond James conferma il rating Strong Buy su Cogent con target price di $60

Raymond James reiterates Strong Buy on Cogent stock with $60 price target

UBS avvia la copertura di Cogent con rating Buy e target di prezzo di $60